Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Myelodysplastic/Myeloproliferative Syndromes

 

Treosulfan + Fludarabine + TBI for Allo HCT for AML and MDS (FHCRC-2272)
Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Investigator: Boglarka Gyurkocza, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Closed;   Study ID: NCT00860574

INC424 for Polycythemia Vera (2490)
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care

Investigator: Bart Lee Scott, MD;   Conditions: Polycythemia Vera;    Status: Recruiting;   Study ID: NCT01243944

Clofarabine, Cytarabine, and G-CSF for Newly Diagnosed Acute Myeloid Leukemia or Advanced MDS (7144)
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS);    Status: Closed;   Study ID: NCT01101880

Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Closed;   Study ID: NCT01141725

Pomalidomide for Myeloproliferative Neoplasms (2465)
A Phase-3, Multi-Center, Randomized, Doubleblind, Placebo-Controlled, Parallel-Group Study To Compare Efficacy And Safety Of Pomalidomide In Subjects With Myeloproliferative Neoplasm, Associated Myelofibrosis And Red Blood Cell-Transfusiondependence

Investigator: Joachim Deeg, MD;   Conditions: Hematologic Malignancies; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Closed;   Study ID: NCT01178281

Lenalidomide With or Without Epoetin Alfa for Myelodysplastic Syndrome
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

Investigator: Fred Appelbaum, MD;   Conditions: Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT00843882

Early Discharge and Outpatient Care MDS and AML Patients
Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML

Investigator: Roland B. Walter, MD, PhD;   Conditions: Myelodysplastic Syndromes, Leukemia;    Status: Recruiting;   Study ID: NCT01235572

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Decitabine + Mitoxantrone Hydrochloride, Etoposide, and Cytarabine for AML or MDS (2652)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01729845

Treosulfan and Fludarabine + Low-Dose TBI as Transplant Conditioning for MDS Patients (2524)
A Randomized Phase II Multi-Center Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS)

Investigator: Joachim Deeg, MD;   Conditions: Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01894477

Azacitidine Plus Best Supportive Care for Low Risk Myelodysplastic Syndrome (2685)
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT01566695

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796